Neumora Therapeutics (NMRA) Net Cash Flow (2022 - 2026)

Neumora Therapeutics' Net Cash Flow history runs 5 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 131.93% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $19.0 million (up 133.89% YoY), while the FY2025 annual figure was $39.2 million, up 116.89% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$35.5 million, down from $53.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $208.1 million in Q3 2023, with the low at -$191.1 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$13.4 million (2022), against an average of -$7.6 million.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 534.44% in 2024, then soared 140.02% in 2025.
• Neumora Therapeutics' Net Cash Flow stood at -$11.6 million in 2022, then slumped by 230.76% to -$38.2 million in 2023, then sank by 249.23% to -$133.6 million in 2024, then jumped by 140.02% to $53.5 million in 2025, then plunged by 166.33% to -$35.5 million in 2026.
• Business Quant data shows NMRA's Net Cash Flow at -$35.5 million in Q1 2026, $53.5 million in Q4 2025, and $4.5 million in Q3 2025.